51 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
14 May 24
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
8:03am
is being evaluated in a Phase 1 safety study, which includes surrogate biomarkers to measure target engagement and clinical efficacy. The single
8-K
EX-99.1
fi4hnywbacbdh km51e3
8 Mar 24
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
8:20am
8-K
EX-99.1
wgcab uc7lmr
3 Nov 23
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
8:10am
8-K
EX-99.1
oa3kkfe6
2 Oct 23
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
12:15pm
8-K
EX-99.1
2tu9q66kc c1
8 Nov 22
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
8:41am
8-K
EX-99.1
p96u4wlqd6t1aeljm
10 May 22
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
8:05am
8-K
EX-10.1
9rrerhg3wnqym4
3 Jan 22
Entry into a Material Definitive Agreement
7:00am
8-K
EX-99.1
vp2k dfol
19 Apr 21
Regulation FD Disclosure
4:22pm
8-K
EX-99.1
u1riohp9a
9 Apr 21
Regulation FD Disclosure
10:01am
8-K
EX-99.1
kf7ptuq5
3 Mar 21
Regulation FD Disclosure
10:05am